Compare · CNC vs GH
CNC vs GH
Side-by-side comparison of Centene Corporation (CNC) and Guardant Health Inc. (GH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and GH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $37.02B, about 1.9x GH ($19.49B).
- Over the past year, CNC is up 101.6% and GH is up 49.2% - CNC leads by 52.4 points.
- GH has been more active in the news (22 items in the past 4 weeks vs 6 for CNC).
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Guardant Health Inc.
- Price
- -
- -
- Market cap
- $37.02B
- $19.49B
- 1M return
- +8.17%
- -9.29%
- 1Y return
- +101.64%
- +49.20%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 6
- 22
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Latest CNC
- For 75 San Joaquin County Families, Affordable Housing May be Within Reach thanks to Health Net
- Ambetter from Meridian Returns to Metro Detroit for 2027 Marketplace Open Enrollment
- Meridian Health Plan of Illinois Announces Nearly $1.2M Partnership with March of Dimes for Local Maternal Healthcare Initiatives
- SEC Form 8-K filed by Centene Corporation
- SEC Form 10-Q filed by Centene Corporation
- CENTENE CORPORATION REPORTS THIRD QUARTER 2026 RESULTS
- CENTENE CORPORATION TO HOST 2026 THIRD QUARTER FINANCIAL RESULTS EARNINGS CALL
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
- PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
Latest GH
- Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Director Azar Alex M Ii converted options into 138 shares, increasing direct ownership by 15% to 1,031 units (SEC Form 4)
- Director Sayer Kevin R was granted 3,149 restricted stock units (SEC Form 4)
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New insider Sayer Kevin R claimed no ownership of stock in the company (SEC Form 3)
- Chief Accounting Officer Parks Robert was granted 18,893 restricted stock units (SEC Form 4)
- New insider Parks Robert claimed no ownership of stock in the company (SEC Form 3)
- Guardant Health Prices $500 Million Convertible Senior Notes Offering
- Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
- Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid